Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP84CS)

• Drug Name: KOJIC ACID Drug Info
• Synonyms: kojic acid; 501-30-4; 5-Hydroxy-2-(hydroxymethyl)-4H-pyran-4-one; 5-Hydroxy-2-(hydroxymethyl)-4-pyrone; 5-Hydroxy-2-hydroxymethyl-4-pyrone; 4H-PYRAN-4-ONE, 5-HYDROXY-2-(HYDROXYMETHYL)-; 5-hydroxy-2-(hydroxymethyl)pyran-4-one; acido kojico; 2-Hydroxymethyl-5-hydroxy-gamma-pyrone; 2-(Hydroxymethyl)-5-hydroxy-4H-pyran-4-one; UNII-6K23F1TT52; CCRIS 4131; 5-Hydroxy-2-hydroxymethyl-4H-4-pyranone; NSC 1942; EINECS 207-922-4; BRN 0120895; Pyran-4-one, 5-hydroxy-2-(hydroxymethyl); 5-Hydroxy-2-hydroxymethyl-4H-pyran-4-one; AI3-02549

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 3840
  ChEBI ID: CHEBI:43572
  CAS Number: CAS 501-30-4
  TTD Drug ID: DMP84CS

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosinase (TYR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[3]
Monobenzone	DMVJS2K	Vitiligo	ED63.0	Approved	[3]
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[4]
Melanoma vaccine	DMQEC6Z	Melanoma	2C30	Phase 3	[5]
Polynoma-1	DM3QDA6	Melanoma	2C30	Phase 2	[6]
MKC-1106-MT	DMXKOW6	Melanoma	2C30	Phase 2	[7]
Multi-epitope tyrosinase/gp100 vaccine	DMN68ZL	Melanoma	2C30	Phase 2	[8]
PMID29130358-Compound-Figure11(3)	DMSME2B	N. A.	N. A.	Patented	[9]
Benzothiazole analog 1	DMHXFCQ	Albinism	EC23.2	Patented	[10]
Monoamine derivative 2	DMAZ6DI	Albinism	EC23.2	Patented	[10]

Drug(s) Affected By Transcription factor E2F8 (E2F8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[11]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[13]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]

Drug(s) Affected By CBY1-interacting BAR domain-containing protein 1 (CIBAR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[22]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
GALLICACID	DM6Y3A0	Discovery agent	N.A.	Investigative	[28]
methyl p-hydroxybenzoate	DMO58UW	Discovery agent	N.A.	Investigative	[29]

Drug(s) Affected By Coiled-coil domain-containing protein 144A (CCDC144A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[30]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[32]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By NF-kappa-B inhibitor epsilon (NFKBIE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[34]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[35]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[36]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Bortezomib	DMNO38U	Leukemia		Approved	[38]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[39]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[33]

Drug(s) Affected By Huntingtin-interacting protein 1 (HIP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[40]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[13]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[44]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]

Drug(s) Affected By Sodium-dependent phosphate transport protein 3 (SLC17A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[46]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[48]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[46]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[17]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]

Drug(s) Affected By Transcription factor E2F3 (E2F3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[50]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[51]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[52]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[53]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[52]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[55]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]

Drug(s) Affected By Fucose-1-phosphate guanylyltransferase (FPGT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[58]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[19]
Nickel chloride	DMI12Y8	Discovery agent	N.A.	Investigative	[59]

Drug(s) Affected By NADH dehydrogenase 1 alpha subcomplex subunit 1 (NDUFA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[61]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[63]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[65]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[65]

Drug(s) Affected By Serine palmitoyltransferase 1 (SPTLC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[67]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[68]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[40]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[69]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[70]
COUMESTROL	DM40TBU	Discovery agent	N.A.	Investigative	[71]

Drug(s) Affected By Claudin-3 (CLDN3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[72]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Sanguinarine	DMDINFS	Dental plaque	DA08.4	Approved	[74]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[75]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[76]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[33]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[77]

Drug(s) Affected By 26S proteasome non-ATPase regulatory subunit 3 (PSMD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
MG-132	DMKA2YS	N. A.	N. A.	Preclinical	[80]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[81]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]
AHPN	DM8G6O4	Discovery agent	N.A.	Investigative	[83]

Drug(s) Affected By Voltage-gated potassium channel subunit beta-3 (KCNAB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Disintegrin and metalloproteinase domain-containing protein 20 (ADAM20)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]

Drug(s) Affected By Transcription factor 21 (TCF21)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[85]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[86]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[87]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[25]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[60]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]

Drug(s) Affected By Cytohesin-3 (CYTH3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[50]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[88]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[90]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[91]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]

Drug(s) Affected By Syntaxin-6 (STX6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[95]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[95]

Drug(s) Affected By Prickle planar cell polarity protein 3 (PRICKLE3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Mediator of RNA polymerase II transcription subunit 14 (MED14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[97]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[98]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[100]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[98]

Drug(s) Affected By Suppression of tumorigenicity 18 protein (ST18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[87]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]

Drug(s) Affected By Heterogeneous nuclear ribonucleoprotein Q (SYNCRIP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[102]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[103]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[44]

Drug(s) Affected By Cell cycle checkpoint protein RAD1 (RAD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[104]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[105]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Arecoline	DMFJZK3	Parkinson disease	8A00.0	Phase 1	[106]
3R14S-OCHRATOXIN A	DM2KEW6	Discovery agent	N.A.	Investigative	[107]
COUMESTROL	DM40TBU	Discovery agent	N.A.	Investigative	[71]

Drug(s) Affected By Transcription factor MafK (MAFK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[108]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[109]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[110]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[91]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]

Drug(s) Affected By Cytohesin-interacting protein (CYTIP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[54]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[111]
Bortezomib	DMNO38U	Leukemia		Approved	[75]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Rigosertib	DMOSTXF	Myelodysplastic syndrome	2A37	Phase 3	[112]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[113]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[114]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[115]

Drug(s) Affected By Leukocyte immunoglobulin-like receptor subfamily B member 5 (LILRB5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Paired amphipathic helix protein Sin3b (SIN3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[116]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[118]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[95]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]

Drug(s) Affected By Hyaluronan mediated motility receptor (HMMR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[119]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[11]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[119]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]

Drug(s) Affected By Probable G-protein coupled receptor 32 (GPR32)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[86]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]
PHENCYCLIDINE	DMQBEYX	Discovery agent	N.A.	Investigative	[121]

Drug(s) Affected By Pre-mRNA-processing factor 40 homolog A (PRPF40A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[123]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[122]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[60]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[95]

Drug(s) Affected By Low-density lipoprotein receptor-related protein 6 (LRP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[124]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[125]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[124]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[126]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[32]

Drug(s) Affected By Sterol O-acyltransferase 2 (SOAT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[33]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[127]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[128]
BRN-3548355	DM4KXT0	N. A.	N. A.	Investigative	[129]

Drug(s) Affected By PRA1 family protein 3 (ARL6IP5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[130]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[131]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[132]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[133]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[134]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]

Drug(s) Affected By Protein cornichon homolog 1 (CNIH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[133]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Nabiximols	DMHKJ5I	Cancer related pain	MG30	Phase 3	[135]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[128]
chloropicrin	DMSGBQA	Discovery agent	N.A.	Investigative	[136]

Drug(s) Affected By Protein transport protein Sec24B (SEC24B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[46]
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[137]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[46]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[138]

Drug(s) Affected By Pre-mRNA-splicing factor SYF2 (SYF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[19]

Drug(s) Affected By Heart- and neural crest derivatives-expressed protein 1 (HAND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[139]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[87]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[140]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Phenylalanine-4-hydroxylase (PAH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[141]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[17]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[140]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Coagulation factor X (F10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[142]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[143]
Estriol	DMOEM2I	Hormone deficiency	5A61.1	Approved	[144]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[145]
Ardeparin	DMYRX8B	Deep vein thrombosis	BD71	Approved	[146]

Drug(s) Affected By Plasma kallikrein (KLKB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[147]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[85]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[142]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[78]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[148]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[142]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[17]

Drug(s) Affected By Annexin A1 (ANXA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[149]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[150]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[151]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[137]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[152]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[132]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[153]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[150]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]

Drug(s) Affected By Amyloid-beta precursor protein (APP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[154]
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[85]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[155]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[156]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[157]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[158]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[159]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Aluminium	DM6ECN9	Hyperhidrosis	EE00	Approved	[160]

Drug(s) Affected By Plasma serine protease inhibitor (SERPINA5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[72]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[44]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
ARZOXIFENE	DMOKCVI	Breast cancer	2C60-2C65	Approved	[161]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[162]

Drug(s) Affected By Eukaryotic translation initiation factor 4E (EIF4E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[163]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[164]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[13]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[165]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[166]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[167]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Momelotinib	DMF98Q0	Myelofibrosis	2A20.2	Approved	[168]
Flurbiprofen	DMGN4BY	Osteoarthritis	FA00-FA05	Approved	[167]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]

Drug(s) Affected By Neutrophil elastase (ELANE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Glyceryl trinitrate	DMF72W3	N. A.	N. A.	Phase 4	[169]
Lipoteichoic acid	DMEMRW0	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[170]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
fMet-Leu-Phe	DMQ391A	N. A.	N. A.	Investigative	[171]
paraquat	DMR8O3X	Discovery agent	N.A.	Investigative	[172]
Aniline	DMLCAR9	N. A.	N. A.	Investigative	[173]

Drug(s) Affected By Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial (PDHA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[13]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[137]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[174]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[88]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[63]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]

Drug(s) Affected By Keratin, type II cytoskeletal 7 (KRT7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[175]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[176]
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[177]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[177]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[67]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[72]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]

Drug(s) Affected By T-cell surface glycoprotein CD3 gamma chain (CD3G)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[179]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[179]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[180]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Intestinal-type alkaline phosphatase (ALPI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[181]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[116]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[116]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]
Wortmannin	DM8EVK5	Haematological malignancy	2B33.Y	Terminated	[181]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[95]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[182]
cycloheximide	DMGDA3C	Discovery agent	N.A.	Investigative	[183]

Drug(s) Affected By Osteopontin (SPP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[184]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[185]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[186]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[187]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[188]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[189]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[190]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[159]

Drug(s) Affected By Thyroid hormone receptor beta (THRB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[191]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[192]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[193]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[194]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[44]

Drug(s) Affected By Ribose-phosphate pyrophosphokinase 2 (PRPS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[67]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[97]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[174]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]

Drug(s) Affected By Fibroblast growth factor 5 (FGF5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[195]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[196]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[197]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[198]
Ardeparin	DMYRX8B	Deep vein thrombosis	BD71	Approved	[199]
Warfarin	DMJYCVW	Atrial fibrillation	BC81.3	Approved	[200]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[65]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[65]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[201]
Suramin	DMTOUY9	African trypanosomiasis	1F51	Phase 1	[202]

Drug(s) Affected By Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[150]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[151]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[13]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[150]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[72]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]

Drug(s) Affected By Bone marrow proteoglycan (PRG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[203]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
3R14S-OCHRATOXIN A	DM2KEW6	Discovery agent	N.A.	Investigative	[204]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[205]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]
Sulforaphane	DMQY3L0	Skin disease	EA00-EM0Z	Investigative	[206]
Butanoic Acid	DMTAJP7	Discovery agent	N.A.	Investigative	[207]

Drug(s) Affected By Beta-3 adrenergic receptor (ADRB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[208]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[209]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Phenylephrine	DMZHUO5	Allergic rhinitis	CA08.0	Approved	[210]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
[3H]CGP12177	DMZN1A3	Discovery agent	N.A.	Investigative	[211]
Cyanopindolol	DMIBLGH	Discovery agent	N.A.	Investigative	[212]
[3H]cAMP	DMZRQU7	Discovery agent	N.A.	Investigative	[213]

Drug(s) Affected By Carboxypeptidase B (CPB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]

Drug(s) Affected By Carboxypeptidase E (CPE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[30]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[214]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[44]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[215]

Drug(s) Affected By T-cell acute lymphocytic leukemia protein 1 (TAL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[216]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[162]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[217]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Tetraspanin-8 (TSPAN8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[218]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[65]
ACYLINE	DM9GRTK	Prostate cancer	2C82.0	Phase 2	[219]

Drug(s) Affected By Transcobalamin-1 (TCN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[111]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[162]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]

Drug(s) Affected By B-cell receptor CD22 (CD22)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[30]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[122]
Bryostatin-1	DM1JOXY	Alzheimer disease	8A20	Phase 2	[220]

Drug(s) Affected By Bone morphogenetic protein 5 (BMP5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[221]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[140]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[87]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[222]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[222]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[140]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[140]

Drug(s) Affected By Sterol carrier protein 2 (SCP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[223]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[224]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[225]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[142]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[223]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]

Drug(s) Affected By Fibroblast growth factor receptor 3 (FGFR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[151]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[13]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[152]
Lenalidomide	DM6Q7U4	Adult T-cell leukemia/lymphoma		Approved	[226]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[226]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[97]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[227]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]

Drug(s) Affected By Aquaporin-1 (AQP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[228]
Acetazolamide	DM1AF5U	Absence epilepsy		Approved	[229]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[230]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[231]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[87]

Drug(s) Affected By Syndecan-4 (SDC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[232]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[233]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[234]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[131]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[139]
Epanova	DMHEAGL	Hypertriglyceridemia	5C80.1	Approved	[235]

Drug(s) Affected By RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[236]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[237]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[238]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[239]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[240]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[241]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[242]
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[243]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[244]

Drug(s) Affected By Homeobox protein OTX1 (OTX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[50]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[245]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[182]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[103]

Drug(s) Affected By Guanylate cyclase soluble subunit alpha-2 (GUCY1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[25]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[246]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[25]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[247]

Drug(s) Affected By Dual specificity protein kinase TTK (TTK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[248]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[249]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[156]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]

Drug(s) Affected By Serum amyloid A-4 protein (SAA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[142]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[250]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[111]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[17]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[91]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[47]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[251]

Drug(s) Affected By Fibrillin-2 (FBN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[252]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[88]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[253]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]

Drug(s) Affected By Protein DEK (DEK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[254]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[131]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[255]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]

Drug(s) Affected By GMP reductase 1 (GMPR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[152]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[256]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[257]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[258]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[25]

Drug(s) Affected By Serine/threonine-protein kinase receptor R3 (ACVRL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[259]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[88]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[122]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[25]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[260]

Drug(s) Affected By Interleukin-6 receptor subunit beta (IL6ST)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[228]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[186]
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[261]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[262]
Lenalidomide	DM6Q7U4	Adult T-cell leukemia/lymphoma		Approved	[263]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[263]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]

Drug(s) Affected By C->U-editing enzyme APOBEC-1 (APOBEC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[264]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Exosome RNA helicase MTR4 (MTREX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[265]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[266]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[267]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[19]

Drug(s) Affected By Mitogen-activated protein kinase 8 (MAPK8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[268]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[269]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[270]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[271]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[272]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[273]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[274]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[275]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[272]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[276]

Drug(s) Affected By ATP-dependent DNA helicase Q1 (RECQL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[104]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[253]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[60]

Drug(s) Affected By Phosphatidylinositol transfer protein beta isoform (PITPNB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[40]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[174]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]

Drug(s) Affected By DNA primase small subunit (PRIM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[248]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[11]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[277]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[156]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]

Drug(s) Affected By CCAAT/enhancer-binding protein delta (CEBPD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[30]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[252]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[132]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[102]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]

Drug(s) Affected By C-C chemokine receptor type 4 (CCR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[147]
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[147]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[278]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[279]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[280]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[281]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]
Sulforaphane	DMQY3L0	Skin disease	EA00-EM0Z	Investigative	[282]

Drug(s) Affected By Dynein light chain Tctex-type 3 (DYNLT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[283]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[58]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[247]
4-hydroxy-2-nonenal	DM2LJFZ	Discovery agent	N.A.	Investigative	[284]

Drug(s) Affected By Ephrin-A3 (EFNA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[143]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[266]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[247]

Drug(s) Affected By Arfaptin-2 (ARFIP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[285]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[22]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[138]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[95]

Drug(s) Affected By Ephrin type-A receptor 4 (EPHA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[286]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[287]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[286]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[97]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Mestranol	DMG3F94	Contraception	QA21	Approved	[286]

Drug(s) Affected By Paired mesoderm homeobox protein 1 (PRRX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[150]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[288]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Indomethacin	DMSC4A7	Bursitis		Approved	[289]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[289]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[290]

Drug(s) Affected By Exportin-2 (CSE1L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[164]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[291]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[292]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[55]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[293]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[293]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]

Drug(s) Affected By Microfibril-associated glycoprotein 4 (MFAP4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[85]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[72]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[133]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[195]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[257]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[294]

Drug(s) Affected By Protein arginine N-methyltransferase 2 (PRMT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[163]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[194]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]

Drug(s) Affected By Heterogeneous nuclear ribonucleoprotein H2 (HNRNPH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[295]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[296]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[297]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Homeobox protein DLX-1 (DLX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[140]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[298]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[298]
Adefovir Dipivoxil	DMMAWY1	Hepatitis B virus infection	1E51.0	Approved	[298]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[298]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[138]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]

Drug(s) Affected By Toll/interleukin-1 receptor domain-containing adapter protein (TIRAP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Diphenylpyraline	DMW4X37	Allergic rhinitis	CA08.0	Approved	[299]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[300]

Drug(s) Affected By Destrin (DSTN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[301]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By COP9 signalosome complex subunit 2 (COPS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[91]
COUMESTROL	DM40TBU	Discovery agent	N.A.	Investigative	[71]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]
taurine	DMVW7N3	Discovery agent	N.A.	Investigative	[302]

Drug(s) Affected By Fibroblast growth factor 12 (FGF12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[85]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[288]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[137]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[280]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]

Drug(s) Affected By Neurocalcin-delta (NCALD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[140]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[87]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[140]

Drug(s) Affected By AP-1 complex subunit sigma-1A (AP1S1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[303]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[303]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[304]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[305]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[306]

Drug(s) Affected By 26S proteasome regulatory subunit 10B (PSMC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[119]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[97]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[307]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[308]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]

Drug(s) Affected By Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[154]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[309]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[310]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[311]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]

Drug(s) Affected By Homeobox protein Nkx-6.1 (NKX6-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]

Drug(s) Affected By Serine/arginine-rich splicing factor 2 (SRSF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[95]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[143]
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[134]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[312]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[104]

Drug(s) Affected By Histone H1.1 (H1-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[195]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[313]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[314]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[81]

Drug(s) Affected By Histone acetyltransferase p300 (EP300)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[315]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[316]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[97]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[317]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[55]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[318]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[319]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]

Drug(s) Affected By Neuroblast differentiation-associated protein AHNAK (AHNAK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[320]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[95]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]

Drug(s) Affected By Ras-GEF domain-containing family member 1B (RASGEF1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[308]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[116]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[321]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[116]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Polypeptide N-acetylgalactosaminyltransferase 1 (GALNT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[322]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[221]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[58]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[65]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[60]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[323]
Nicotinamide mononucleotide	DMW1LKP	N. A.	N. A.	Preclinical	[324]

Drug(s) Affected By Bone marrow stromal antigen 2 (BST2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[325]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[325]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[152]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[326]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[325]

Drug(s) Affected By Phosducin-like protein (PDCL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Bortezomib	DMNO38U	Leukemia		Approved	[75]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
EMODIN	DMAEDQG	Coronavirus Disease 2019 (COVID-19)	1D6Y	Terminated	[327]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 2 (BIRC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[328]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[329]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[330]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[164]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[331]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[332]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[333]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[334]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[335]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[336]

Drug(s) Affected By Apoptosis-stimulating of p53 protein 2 (TP53BP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[322]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[55]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[17]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[91]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[337]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[118]

Drug(s) Affected By Krueppel-like factor 5 (KLF5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[119]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[234]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]

Drug(s) Affected By FERM and PDZ domain-containing protein 4 (FRMPD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[338]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]

Drug(s) Affected By N-alpha-acetyltransferase 25, NatB auxiliary subunit (NAA25)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[133]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[339]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[140]

Drug(s) Affected By Polycomb protein SUZ12 (SUZ12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[340]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[341]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[342]

Drug(s) Affected By Translocating chain-associated membrane protein 2 (TRAM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[194]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[343]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[58]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[25]

Drug(s) Affected By DAZ-associated protein 2 (DAZAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Bortezomib	DMNO38U	Leukemia		Approved	[75]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[25]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[103]
chloropicrin	DMSGBQA	Discovery agent	N.A.	Investigative	[136]

Drug(s) Affected By Rab3 GTPase-activating protein catalytic subunit (RAB3GAP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[33]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[122]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[95]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[88]

Drug(s) Affected By Lysine--tRNA ligase (KARS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[344]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[95]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[267]
AHPN	DM8G6O4	Discovery agent	N.A.	Investigative	[83]

Drug(s) Affected By Cyclin-dependent kinase 10 (CDK10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[30]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[154]
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[345]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[346]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[347]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[348]

Drug(s) Affected By Translocating chain-associated membrane protein 1 (TRAM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[349]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[350]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[138]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[351]

Drug(s) Affected By Septin-7 (SEPTIN7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[352]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[70]
AHPN	DM8G6O4	Discovery agent	N.A.	Investigative	[83]

Drug(s) Affected By Protein SSX1 (SSX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[353]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[182]

Drug(s) Affected By Hepatic leukemia factor (HLF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[111]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]

Drug(s) Affected By Bcl-2-related protein A1 (BCL2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[354]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[325]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[214]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[355]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[356]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[357]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[325]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[197]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]

Drug(s) Affected By Nuclear factor interleukin-3-regulated protein (NFIL3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[358]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[119]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[11]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[156]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]

Drug(s) Affected By NADP-dependent malic enzyme, mitochondrial (ME3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[143]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[88]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[343]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[140]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[91]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]

Drug(s) Affected By Collagen alpha-1(XXIV) chain (COL24A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[298]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[308]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By La-related protein 7 (LARP7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[44]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[40]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[203]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[58]

Drug(s) Affected By Midnolin (MIDN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[359]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]

Drug(s) Affected By mRNA export factor GLE1 (GLE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[71]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]
COUMESTROL	DM40TBU	Discovery agent	N.A.	Investigative	[71]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]

Drug(s) Affected By Ephrin type-A receptor 10 (EPHA10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[360]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[361]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[361]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[360]

Drug(s) Affected By Deoxynucleotidyltransferase terminal-interacting protein 2 (DNTTIP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[17]

Drug(s) Affected By PGC-1 and ERR-induced regulator in muscle protein 1 (PERM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[362]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]

Drug(s) Affected By Outer dynein arm-docking complex subunit 2 (ODAD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[362]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[25]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[32]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[103]

Drug(s) Affected By Cytosolic carboxypeptidase 6 (AGBL4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]

Drug(s) Affected By Rho guanine nucleotide exchange factor 16 (ARHGEF16)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[95]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[194]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Seocalcitol	DMKL9QO	Rickets	5B57	Phase 3	[363]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Lysine-specific demethylase 9 (RSBN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[260]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[339]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[103]

Drug(s) Affected By Lysine-specific demethylase 4D (KDM4D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[364]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[365]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[32]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[103]

Drug(s) Affected By 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial (HIBCH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[85]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[13]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]

Drug(s) Affected By Epithelial splicing regulatory protein 1 (ESRP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[345]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[366]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[72]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[33]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[58]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[65]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[65]

Drug(s) Affected By Proprotein convertase subtilisin/kexin type 4 (PCSK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[367]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Protein O-glucosyltransferase 2 (POGLUT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[111]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[81]

Drug(s) Affected By Olfactomedin-like protein 1 (OLFML1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[97]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[72]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[362]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[25]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[351]

Drug(s) Affected By Amelotin (AMTN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[32]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By RNA-binding protein MEX3B (MEX3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[197]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]

Drug(s) Affected By N-acetyl-beta-glucosaminyl-glycoprotein 4-beta-N-acetylgalactosaminyltransferase 1 (B4GALNT4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[317]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]
Maleic Acid	DM4L0R7	Discovery agent	N.A.	Investigative	[368]

Drug(s) Affected By tRNA methyltransferase 10 homolog C (TRMT10C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[197]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Centromere protein Q (CENPQ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[369]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[370]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[32]

Drug(s) Affected By E3 ubiquitin-protein transferase MAEA (MAEA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]

Drug(s) Affected By Aprataxin (APTX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[50]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Kinectin (KTN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[67]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[371]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[40]
Bortezomib	DMNO38U	Leukemia		Approved	[75]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[71]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[372]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[60]

Drug(s) Affected By ATP-binding cassette sub-family A member 13 (ABCA13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[373]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[127]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[95]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[103]

Drug(s) Affected By Poly(ADP-ribose) glycohydrolase (PARG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[95]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]

Drug(s) Affected By Osteopetrosis-associated transmembrane protein 1 (OSTM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[374]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[375]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[307]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[376]

Drug(s) Affected By Ras association domain-containing protein 3 (RASSF3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[194]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[377]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[138]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[140]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]

Drug(s) Affected By Coiled-coil domain-containing protein 50 (CCDC50)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[132]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Indomethacin	DMSC4A7	Bursitis		Approved	[378]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[379]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]

Drug(s) Affected By Cell division cycle and apoptosis regulator protein 1 (CCAR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[40]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[193]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[40]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[40]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[380]
Bortezomib	DMNO38U	Leukemia		Approved	[381]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[382]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]

Drug(s) Affected By F-box only protein 16 (FBXO16)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[246]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[140]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[25]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]

Drug(s) Affected By PEX5-related protein (PEX5L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[30]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[25]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[19]

Drug(s) Affected By Uncharacterized protein C1orf87 (C1ORF87)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]

Drug(s) Affected By Dedicator of cytokinesis protein 4 (DOCK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[194]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[140]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[290]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[140]

Drug(s) Affected By Proline-rich protein 18 (PRR18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[19]

Drug(s) Affected By Fibrinogen C domain-containing protein 1 (FIBCD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[246]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[383]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[140]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]

Drug(s) Affected By BTB/POZ domain-containing protein KCTD17 (KCTD17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Interleukin-22 receptor subunit alpha-1 (IL22RA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[384]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[137]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[142]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[245]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]

Drug(s) Affected By Transmembrane protein 217 (TMEM217)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Uncharacterized protein FAM241A (FAM241A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[133]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[142]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[385]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[88]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[386]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]

Drug(s) Affected By Uncharacterized protein C1orf131 (C1ORF131)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[141]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[339]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[247]

Drug(s) Affected By Terminal nucleotidyltransferase 4B (TENT4B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[42]
Bleomycin	DMNER5S	Cervical cancer	2C77.0	Approved	[42]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[387]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]
Scriptaid	DM9JZ21	Solid tumour/cancer	2A00-2F9Z	Preclinical	[42]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]

Drug(s) Affected By G-protein coupled receptor 26 (GPR26)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By SHC SH2 domain-binding protein 1 (SHCBP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[11]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[47]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[195]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[141]

Drug(s) Affected By Diphosphoinositol polyphosphate phosphohydrolase 3-alpha (NUDT10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[40]
DIADENOSINE TETRAPHOSPHATE	DMTJOEL	Cardiac arrhythmias	BC9Z	Phase 2	[388]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Speedy protein E1 (SPDYE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[111]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[19]

Drug(s) Affected By Neuroligin-2 (NLGN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[30]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[139]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[88]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[25]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]

Drug(s) Affected By piRNA biogenesis protein EXD1 (EXD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]

Drug(s) Affected By Claudin domain-containing protein 2 (CLDND2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]

Drug(s) Affected By Atypical kinase COQ8A, mitochondrial (COQ8A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[389]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[390]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[104]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[253]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[348]
Artesunate	DMR27C8	Infection of P. falciparum	1F40	Approved	[391]

Drug(s) Affected By Large ribosomal subunit protein uL30m (MRPL30)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[143]
Bortezomib	DMNO38U	Leukemia		Approved	[75]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[392]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[71]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[70]

Drug(s) Affected By Serine/threonine-protein kinase BRSK1 (BRSK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[142]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[361]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
THAPSIGARGIN	DMDMQIE	N. A.	N. A.	Preclinical	[393]

Drug(s) Affected By 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[111]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[17]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]

Drug(s) Affected By RB1-inducible coiled-coil protein 1 (RB1CC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[394]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[371]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[307]
Bortezomib	DMNO38U	Leukemia		Approved	[75]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[395]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[123]

Drug(s) Affected By Centrosomal protein of 192 kDa (CEP192)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[141]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[215]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[323]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[95]
COUMESTROL	DM40TBU	Discovery agent	N.A.	Investigative	[71]

Drug(s) Affected By Docking protein 4 (DOK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[396]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[397]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[87]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[396]

Drug(s) Affected By Serine/threonine-protein phosphatase 4 regulatory subunit 1 (PPP4R1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[362]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[95]

Drug(s) Affected By C-type lectin domain family 4 member C (CLEC4C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[182]

Drug(s) Affected By Nucleolar complex protein 3 homolog (NOC3L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[65]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]

Drug(s) Affected By Secreted and transmembrane protein 1 (SECTM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[137]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[298]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[398]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Lucanthone	DMZLBUO	Solid tumour/cancer	2A00-2F9Z	Approved	[399]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[25]

Drug(s) Affected By Tumor necrosis factor alpha-induced protein 8-like protein 1 (TNFAIP8L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[25]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
GALLICACID	DM6Y3A0	Discovery agent	N.A.	Investigative	[28]

Drug(s) Affected By Uncharacterized protein C1orf54 (C1ORF54)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[400]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[293]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[293]

Drug(s) Affected By Connector enhancer of kinase suppressor of ras 2 (CNKSR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[50]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[401]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[140]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[361]

Drug(s) Affected By StAR-related lipid transfer protein 8 (STARD8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[111]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[293]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[293]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[402]

Drug(s) Affected By Tetratricopeptide repeat protein 9A (TTC9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[72]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[133]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[111]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[361]

Drug(s) Affected By Symplekin (SYMPK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[403]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[404]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[122]
Afimoxifene	DMFORDT	Breast cancer	2C60-2C65	Phase 2	[404]

Drug(s) Affected By TATA-binding protein-associated factor 2N (TAF15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[358]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[102]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[362]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[33]

Drug(s) Affected By Histone H2A type 1-C (H2AC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[322]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[61]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[111]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[405]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[406]

Drug(s) Affected By BLOC-2 complex member HPS3 (HPS3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Bortezomib	DMNO38U	Leukemia		Approved	[75]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[407]

Drug(s) Affected By Sodium-coupled neutral amino acid transporter 4 (SLC38A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[48]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[362]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[17]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[290]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]

Drug(s) Affected By Oxysterol-binding protein 2 (OSBP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[408]
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[246]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[293]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[293]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[409]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[410]

Drug(s) Affected By Endothelial cell-selective adhesion molecule (ESAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[47]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[411]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[17]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[205]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[247]

Drug(s) Affected By Peptidyl-prolyl cis-trans isomerase FKBP10 (FKBP10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[13]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[412]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[246]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[198]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Probable G-protein coupled receptor 146 (GPR146)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[52]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[245]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[247]

Drug(s) Affected By PPP2R1A-PPP2R2A-interacting phosphatase regulator 1 (PABIR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[95]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[413]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[95]

Drug(s) Affected By Phosphopentomutase (PGM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[222]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[138]

Drug(s) Affected By PDZ and LIM domain protein 2 (PDLIM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[385]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[246]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[60]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[344]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Lymphokine-activated killer T-cell-originated protein kinase (PBK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[11]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[156]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[414]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]

Drug(s) Affected By Small integral membrane protein 8 (SMIM8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[323]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Exocyst complex component 2 (EXOC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[61]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[17]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]

Drug(s) Affected By Putative nuclease HARBI1 (HARBI1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[351]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]

Drug(s) Affected By Coenzyme Q-binding protein COQ10 homolog A, mitochondrial (COQ10A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[389]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[293]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[63]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[127]

Drug(s) Affected By Nectin-4 (NECTIN4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[415]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[72]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[416]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]

Drug(s) Affected By Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 3 (AGAP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[194]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[403]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[123]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[351]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[417]
GALLICACID	DM6Y3A0	Discovery agent	N.A.	Investigative	[28]

Drug(s) Affected By Gasdermin-A (GSDMA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[418]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]

Drug(s) Affected By Structural maintenance of chromosomes protein 6 (SMC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[25]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Bortezomib	DMNO38U	Leukemia		Approved	[75]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Vitamin C	DMXJ7O8	Adenocarcinoma	2D40	Approved	[419]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[60]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]

Drug(s) Affected By MAP7 domain-containing protein 2 (MAP7D2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[152]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[140]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]

Drug(s) Affected By Translocation protein SEC62 (SEC62)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[307]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[390]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[379]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]

Drug(s) Affected By MyoD family inhibitor (MDFI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[88]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[420]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[32]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[421]

Drug(s) Affected By Histone H2A type 1-J (H2AC14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[408]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[422]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[88]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Lucanthone	DMZLBUO	Solid tumour/cancer	2A00-2F9Z	Approved	[399]
Berberine	DMC5Q8X	N. A.	N. A.	Phase 4	[423]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[127]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Cyclic AMP-dependent transcription factor ATF-6 beta (ATF6B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[50]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[345]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[285]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[424]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[255]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[246]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Spermatogenesis-associated protein 25 (SPATA25)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[369]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]

Drug(s) Affected By Phosphatidylinositol N-acetylglucosaminyltransferase subunit Q (PIGQ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By PAXIP1-associated glutamate-rich protein 1 (PAGR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[36]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[58]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[95]

Drug(s) Affected By Mitochondrial ornithine transporter 2 (SLC25A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[425]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[426]
Mivebresib	DMCPF90	Acute myeloid leukaemia	2A60	Phase 1	[426]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By G-protein coupled receptor 61 (GPR61)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Eukaryotic translation initiation factor 5A-2 (EIF5A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[30]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[427]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[194]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]

Drug(s) Affected By Pseudouridylate synthase PUS7L (PUS7L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[116]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[361]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By RNA-binding protein 38 (RBM38)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[390]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]

Drug(s) Affected By Thioredoxin-related transmembrane protein 1 (TMX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[104]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[71]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[71]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Frizzled-8 (FZD8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[233]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[428]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[429]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[58]
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[430]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[140]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Pecanex-like protein 3 (PCNX3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[95]

Drug(s) Affected By CXADR-like membrane protein (CLMP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[152]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[133]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[418]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[32]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Nucleolar protein 11 (NOL11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[97]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[367]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Calcium-binding protein 39-like (CAB39L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[366]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[429]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[87]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
PEITC	DMOMN31	Prostate cancer	2C82.0	Phase 2	[431]

Drug(s) Affected By Melanoma-associated antigen F1 (MAGEF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[22]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[33]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[91]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[113]

Drug(s) Affected By Leucine-rich repeat-containing protein 4 (LRRC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[362]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[432]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[58]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[140]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[432]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[103]

Drug(s) Affected By Copine-5 (CPNE5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Triggering receptor expressed on myeloid cells 1 (TREM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[72]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[230]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[162]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[418]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[433]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[434]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[127]
Nickel chloride	DMI12Y8	Discovery agent	N.A.	Investigative	[434]

Drug(s) Affected By Protein C12orf4 (FERRY3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[60]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[113]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[323]

Drug(s) Affected By Adenosine 5'-monophosphoramidase HINT3 (HINT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[371]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[103]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[91]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Inner centromere protein (INCENP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[435]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]

Drug(s) Affected By Muscleblind-like protein 1 (MBNL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Bortezomib	DMNO38U	Leukemia		Approved	[75]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[215]
Indomethacin	DMSC4A7	Bursitis		Approved	[378]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]

Drug(s) Affected By Cytochrome P450 26B1 (CYP26B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[436]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[194]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[340]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[437]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[265]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[293]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[343]

Drug(s) Affected By Ras-related protein Rab-6B (RAB6B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[133]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[58]
OTX-015	DMI8RG1	Acute myeloid leukaemia	2A60	Phase 1/2	[426]
Mivebresib	DMCPF90	Acute myeloid leukaemia	2A60	Phase 1	[426]

Drug(s) Affected By Alkaline ceramidase 3 (ACER3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[362]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By DDB1- and CUL4-associated factor 13 (DCAF13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Bortezomib	DMNO38U	Leukemia		Approved	[75]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[267]

Drug(s) Affected By Asparagine synthetase domain-containing protein 1 (ASNSD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[88]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]

Drug(s) Affected By Glucose-fructose oxidoreductase domain-containing protein 1 (GFOD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[36]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[246]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]

Drug(s) Affected By Torsin-4A (TOR4A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[81]

Drug(s) Affected By Programmed cell death 1 ligand 1 (CD274)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[438]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[439]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[119]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[440]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[194]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[441]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]

Drug(s) Affected By Dentin sialophosphoprotein (DSPP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[184]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[442]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[443]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[444]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[362]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[411]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[348]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[361]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[445]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[127]

Drug(s) Affected By Centrosomal protein of 72 kDa (CEP72)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[95]

Drug(s) Affected By Kelch-like protein 13 (KLHL13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[111]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
THAPSIGARGIN	DMDMQIE	N. A.	N. A.	Preclinical	[446]

Drug(s) Affected By Melanoma-associated antigen C2 (MAGEC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]

Drug(s) Affected By Cathepsin Z (CTSZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[447]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[386]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Alpha-catulin (CTNNAL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[30]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[277]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[137]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[97]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[307]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]

Drug(s) Affected By Switch-associated protein 70 (SWAP70)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[30]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[203]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]

Drug(s) Affected By Transmembrane protein 59-like (TMEM59L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[362]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[448]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[17]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[247]

Drug(s) Affected By POU domain, class 2, transcription factor 3 (POU2F3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[30]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[139]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[140]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[140]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[115]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[103]

Drug(s) Affected By BAG family molecular chaperone regulator 5 (BAG5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[176]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[55]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[104]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[449]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[60]
EMODIN	DMAEDQG	Coronavirus Disease 2019 (COVID-19)	1D6Y	Terminated	[327]
COUMESTROL	DM40TBU	Discovery agent	N.A.	Investigative	[71]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[82]

Drug(s) Affected By Cell cycle progression protein 1 (CCPG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[30]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[35]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ampicillin	DMHWE7P	Acute epiglottitis		Approved	[47]
Bortezomib	DMNO38U	Leukemia		Approved	[35]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]

Drug(s) Affected By Two pore channel protein 1 (TPCN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[85]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[298]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[298]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[298]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[298]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[298]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[116]

Drug(s) Affected By Carbonic anhydrase 14 (CA14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[261]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[162]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[118]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Zinc finger protein PLAGL1 (PLAGL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[384]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Riboflavin	DM8YMWE	Acne vulgaris	ED80	Approved	[450]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[76]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[377]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]

Drug(s) Affected By Collagen alpha-1(XVII) chain (COL17A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[177]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[177]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[72]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[177]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[411]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Ximelegatran	DMU8ANS	Myocardial infarction	BA41-BA43	Approved	[451]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[264]

Drug(s) Affected By Regulating synaptic membrane exocytosis protein 2 (RIMS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[142]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[452]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[30]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[103]

Drug(s) Affected By Acetylcholinesterase collagenic tail peptide (COLQ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]

Drug(s) Affected By Dexamethasone-induced Ras-related protein 1 (RASD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[408]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[142]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[140]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[88]

Drug(s) Affected By Disks large-associated protein 4 (DLGAP4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[137]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[75]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[71]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[25]

Drug(s) Affected By CDAN1-interacting nuclease 1 (CDIN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[32]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[81]

Drug(s) Affected By DmX-like protein 1 (DMXL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[453]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[42]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[453]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[371]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[22]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]

Drug(s) Affected By Diacylglycerol lipase-alpha (DAGLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[454]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[91]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[122]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[27]
ACEA	DMWX3HT	Discovery agent	N.A.	Investigative	[455]

Drug(s) Affected By Protein PRRC2C (PRRC2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[30]
Selenium	DM25CGV	N. A.	N. A.	Approved	[60]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[95]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[132]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]

Drug(s) Affected By Olfactory receptor 51B4 (OR51B4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[254]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[19]

Drug(s) Affected By Sorting nexin-10 (SNX10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[203]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[257]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[84]

Drug(s) Affected By Sodium channel protein type 10 subunit alpha (SCN10A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Cytochrome c oxidase subunit 1 (COX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[456]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[457]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[458]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[97]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[326]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[317]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Chloramphenicol	DMFXEWT	Bacterial infection	1A00-1C4Z	Approved	[459]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[460]
Nicotinamide	DMUPE07	Acne vulgaris	ED80	Approved	[458]

Drug(s) Affected By Ferritin heavy chain (FTH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[461]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[462]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[463]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[50]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[156]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[464]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[465]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[132]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[298]

Drug(s) Affected By Interleukin-6 (IL6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[325]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[466]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[408]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[467]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[468]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[469]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[470]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[471]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[472]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[325]

Drug(s) Affected By Melanocyte-stimulating hormone receptor (MC1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[458]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[473]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[56]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[33]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[49]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[474]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[474]
GUAIACOL	DMN4E7T	N. A.	N. A.	Phase 3	[474]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[474]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosinase (TYR)	TTULVH8	TYRO_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD)	OTPSXPSF	ACMSD_HUMAN	Gene/Protein Processing	[2]
26S proteasome non-ATPase regulatory subunit 3 (PSMD3)	OT585WY8	PSMD3_HUMAN	Gene/Protein Processing	[2]
26S proteasome regulatory subunit 10B (PSMC6)	OTG8997V	PRS10_HUMAN	Gene/Protein Processing	[2]
3-hydroxyisobutyryl-CoA hydrolase, mitochondrial (HIBCH)	OTU2VHWR	HIBCH_HUMAN	Gene/Protein Processing	[2]
Acetylcholinesterase collagenic tail peptide (COLQ)	OT4BHUGQ	COLQ_HUMAN	Gene/Protein Processing	[2]
Adenosine 5'-monophosphoramidase HINT3 (HINT3)	OTJGDLB6	HINT3_HUMAN	Gene/Protein Processing	[2]
Alkaline ceramidase 3 (ACER3)	OTIVQBG5	ACER3_HUMAN	Gene/Protein Processing	[2]
Alpha-catulin (CTNNAL1)	OTESJ6JD	CTNL1_HUMAN	Gene/Protein Processing	[2]
Amelotin (AMTN)	OTXAMT4V	AMTN_HUMAN	Gene/Protein Processing	[2]
Amyloid-beta precursor protein (APP)	OTKFD7R4	A4_HUMAN	Gene/Protein Processing	[2]

References

• [1] A novel ring-expanded product with enhanced tyrosinase inhibitory activity from classical Fe-catalyzed oxidation of rosmarinic acid, a potent antio... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7393-6.
• [2] Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells. Biol Pharm Bull. 2006 Apr;29(4):655-69.
• [3] Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5.
• [4] Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
• [5] National Cancer Institute Drug Dictionary (drug id 685201).
• [6] An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
• [7] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [8] ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
• [9] Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
• [10] Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
• [11] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [12] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [13] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [14] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [15] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [16] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [17] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [18] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [19] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [20] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [21] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [22] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [23] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [24] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [25] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [26] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [27] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [28] Gene expression profile analysis of gallic acid-induced cell death process. Sci Rep. 2021 Aug 18;11(1):16743. doi: 10.1038/s41598-021-96174-1.
• [29] Transcriptome dynamics of alternative splicing events revealed early phase of apoptosis induced by methylparaben in H1299 human lung carcinoma cells. Arch Toxicol. 2020 Jan;94(1):127-140. doi: 10.1007/s00204-019-02629-w. Epub 2019 Nov 20.
• [30] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [31] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [32] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [33] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [34] Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
• [35] Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet Cytogenet. 2010 Jun;199(2):110-20. doi: 10.1016/j.cancergencyto.2010.02.010.
• [36] A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013 Feb;13(1):94-104. doi: 10.1038/tpj.2011.48. Epub 2011 Nov 15.
• [37] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [38] Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene. 2005 Jan 13;24(3):419-30. doi: 10.1038/sj.onc.1208212.
• [39] Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
• [40] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [41] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [42] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [43] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [44] Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
• [45] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [46] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [47] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [48] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [49] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [50] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [51] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [52] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [53] Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. J Cell Biochem. 2010 Dec 15;111(6):1546-55. doi: 10.1002/jcb.22886.
• [54] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [55] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [56] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [57] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [58] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [59] The contact allergen nickel triggers a unique inflammatory and proangiogenic gene expression pattern via activation of NF-kappaB and hypoxia-inducible factor-1alpha. J Immunol. 2007 Mar 1;178(5):3198-207.
• [60] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [61] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [62] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [63] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [64] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [65] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [66] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [67] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [68] Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization. Autophagy. 2016 Nov;12(11):2213-2229. doi: 10.1080/15548627.2016.1213927. Epub 2016 Sep 16.
• [69] Systematic transcriptome-based comparison of cellular adaptive stress response activation networks in hepatic stem cell-derived progeny and primary human hepatocytes. Toxicol In Vitro. 2021 Jun;73:105107. doi: 10.1016/j.tiv.2021.105107. Epub 2021 Feb 3.
• [70] Alternatives for the worse: Molecular insights into adverse effects of bisphenol a and substitutes during human adipocyte differentiation. Environ Int. 2021 Nov;156:106730. doi: 10.1016/j.envint.2021.106730. Epub 2021 Jun 27.
• [71] Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
• [72] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [73] Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial. Inflamm Bowel Dis. 2019 May 4;25(6):1006-1018. doi: 10.1093/ibd/izz017.
• [74] Anti-invasive activity of sanguinarine through modulation of tight junctions and matrix metalloproteinase activities in MDA-MB-231 human breast carcinoma cells. Chem Biol Interact. 2009 May 15;179(2-3):185-91. doi: 10.1016/j.cbi.2008.11.009. Epub 2008 Nov 21.
• [75] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [76] Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci. 2006 Jan;97(1):64-71.
• [77] Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. J Appl Toxicol. 2023 Aug;43(8):1214-1224. doi: 10.1002/jat.4457. Epub 2023 Mar 11.
• [78] A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
• [79] Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
• [80] Proteasome inhibition creates a chromatin landscape favorable to RNA Pol II processivity. J Biol Chem. 2020 Jan 31;295(5):1271-1287. doi: 10.1074/jbc.RA119.011174. Epub 2019 Dec 5.
• [81] Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
• [82] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [83] ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: modulation of intracellular calcium homeostasis. Blood. 2004 Jan 1;103(1):194-207.
• [84] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [85] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [86] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [87] Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
• [88] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [89] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [90] Proteomic analysis of antiproliferative effects by treatment of 5-fluorouracil in cervical cancer cells. DNA Cell Biol. 2004 Nov;23(11):769-76.
• [91] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [92] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [93] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [94] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [95] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [96] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [97] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [98] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [99] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [100] Changes in gene expressions elicited by physiological concentrations of genistein on human endometrial cancer cells. Mol Carcinog. 2006 Oct;45(10):752-63.
• [101] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [102] Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
• [103] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [104] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [105] Caffeine disrupts ataxia telangiectasia mutated gene-related pathways and exacerbates acetaminophen toxicity in human fetal immortalized hepatocytes. Toxicology. 2021 Jun 15;457:152811. doi: 10.1016/j.tox.2021.152811. Epub 2021 May 7.
• [106] Characterization of arecoline-induced effects on cytotoxicity in normal human gingival fibroblasts by global gene expression profiling. Toxicol Sci. 2007 Nov;100(1):66-74.
• [107] Linking site-specific loss of histone acetylation to repression of gene expression by the mycotoxin ochratoxin A. Arch Toxicol. 2018 Feb;92(2):995-1014.
• [108] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [109] Analysis of the transcriptional regulation of cancer-related genes by aberrant DNA methylation of the cis-regulation sites in the promoter region during hepatocyte carcinogenesis caused by arsenic. Oncotarget. 2015 Aug 28;6(25):21493-506. doi: 10.18632/oncotarget.4085.
• [110] Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
• [111] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [112] ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res. 2012 Apr 1;18(7):1979-91. doi: 10.1158/1078-0432.CCR-11-2113. Epub 2012 Feb 20.
• [113] Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization. Mol Immunol. 2007 May;44(12):3222-33.
• [114] Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Int J Cancer. 2015 May 1;136(9):2055-64.
• [115] Comparison of transcriptome expression alterations by chronic exposure to low-dose bisphenol A in different subtypes of breast cancer cells. Toxicol Appl Pharmacol. 2019 Dec 15;385:114814. doi: 10.1016/j.taap.2019.114814. Epub 2019 Nov 9.
• [116] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [117] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [118] New insights into BaP-induced toxicity: role of major metabolites in transcriptomics and contribution to hepatocarcinogenesis. Arch Toxicol. 2016 Jun;90(6):1449-58.
• [119] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [120] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [121] Effects of Agricultural Organic Dusts on Human Lung-Resident Mesenchymal Stem (Stromal) Cell Function. Toxicol Sci. 2018 Apr 1;162(2):635-644. doi: 10.1093/toxsci/kfx286.
• [122] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [123] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [124] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [125] Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells initro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology. 2017 Jun;152(8):2022-2036.
• [126] The LRP6 functional mutation rs2302685 contributes to individual susceptibility to alcoholic liver injury related to the Wnt/-catenin-TCF1-CYP2E1 signaling pathway. Arch Toxicol. 2019 Jun;93(6):1679-1695. doi: 10.1007/s00204-019-02447-0. Epub 2019 Apr 11.
• [127] Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
• [128] Comprehensive analysis of transcriptomic changes induced by low and high doses of bisphenol A in HepG2 spheroids in vitro and rat liver in vivo. Environ Res. 2019 Jun;173:124-134. doi: 10.1016/j.envres.2019.03.035. Epub 2019 Mar 18.
• [129] Gene expression profiles in HPV-immortalized human cervical cells treated with the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Chem Biol Interact. 2009 Feb 12;177(3):173-80. doi: 10.1016/j.cbi.2008.10.051. Epub 2008 Nov 6.
• [130] JWA, a novel signaling molecule, involved in all-trans retinoic acid induced differentiation of HL-60 cells. J Biomed Sci. 2006 May;13(3):357-71. doi: 10.1007/s11373-005-9068-0. Epub 2006 Feb 9.
• [131] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [132] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [133] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [134] Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15;66(24):12009-18.
• [135] Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. Eur J Neurol. 2018 Jul;25(7):934-e70. doi: 10.1111/ene.13623. Epub 2018 Apr 16.
• [136] Transcriptomic analysis of human primary bronchial epithelial cells after chloropicrin treatment. Chem Res Toxicol. 2015 Oct 19;28(10):1926-35.
• [137] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [138] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [139] Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
• [140] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [141] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [142] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [143] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [144] Vascular complications of long-term oestrogen therapy. Front Horm Res. 1977;5:174-91. doi: 10.1159/000401993.
• [145] Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. Oncol Rep. 2008 Jun;19(6):1627-34.
• [146] Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery. Blood Coagul Fibrinolysis. 1993 Dec;4 Suppl 1:S33-5; discussion S37-8.
• [147] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [148] In vitro and in vivo modulation of testosterone mediated alterations in apoptosis related proteins by [6]-gingerol. Mol Nutr Food Res. 2007 Dec;51(12):1492-502. doi: 10.1002/mnfr.200700197.
• [149] Protein expression profiling identifies molecular targets of quercetin as a major dietary flavonoid in human colon cancer cells. Proteomics. 2004 Jul;4(7):2160-74.
• [150] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [151] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [152] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [153] Proteomics analysis of the proliferative effect of low-dose ouabain on human endothelial cells. Biol Pharm Bull. 2007 Feb;30(2):247-53. doi: 10.1248/bpb.30.247.
• [154] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [155] Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007 Apr;101(1):77-86. doi: 10.1111/j.1471-4159.2006.04375.x. Epub 2007 Jan 4.
• [156] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [157] Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J Struct Biol. 2000 Jun;130(2-3):209-16. doi: 10.1006/jsbi.2000.4285.
• [158] Increased processing of APLP2 and APP with concomitant formation of APP intracellular domains in BDNF and retinoic acid-differentiated human neuroblastoma cells. J Neurochem. 2005 Nov;95(4):1059-68. doi: 10.1111/j.1471-4159.2005.03440.x. Epub 2005 Sep 7.
• [159] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [160] Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. J Alzheimers Dis. 2005 Nov;8(2):117-27; discussion 209-15. doi: 10.3233/jad-2005-8204.
• [161] The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells. Mol Cell Endocrinol. 2004 Apr 30;219(1-2):27-36. doi: 10.1016/j.mce.2004.02.003.
• [162] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [163] Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Toxicol Appl Pharmacol. 2022 Jan 15;435:115829. doi: 10.1016/j.taap.2021.115829. Epub 2021 Dec 14.
• [164] Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
• [165] Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. Mol Cancer Res. 2018 Jan;16(1):32-46. doi: 10.1158/1541-7786.MCR-17-0397. Epub 2017 Oct 17.
• [166] A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
• [167] The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of p75 NTR in prostate cancer cells. Cancer Res. 2007 Dec 1;67(23):11402-10. doi: 10.1158/0008-5472.CAN-07-1792.
• [168] The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. Biomed Pharmacother. 2016 Aug;82:595-605. doi: 10.1016/j.biopha.2016.05.029. Epub 2016 Jun 9.
• [169] Cardiopulmonary bypass exacerbates oxidative stress but does not increase proinflammatory cytokine release in patients with diabetes compared with patients without diabetes: regulatory effects of exogenous nitric oxide. J Thorac Cardiovasc Surg. 2000 Jul;120(1):1-11. doi: 10.1067/mtc.2000.106835.
• [170] Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens. Antimicrob Agents Chemother. 2001 May;45(5):1547-9. doi: 10.1128/AAC.45.5.1547-1549.2001.
• [171] 2-(2-Fluorobenzamido)benzoate ethyl ester (EFB-1) inhibits superoxide production by human neutrophils and attenuates hemorrhagic shock-induced organ dysfunction in rats. Free Radic Biol Med. 2011 Jun 15;50(12):1737-48. doi: 10.1016/j.freeradbiomed.2011.03.026. Epub 2011 Mar 30.
• [172] CD34+ derived macrophage and dendritic cells display differential responses to paraquat. Toxicol In Vitro. 2021 Sep;75:105198. doi: 10.1016/j.tiv.2021.105198. Epub 2021 Jun 9.
• [173] Similarities between human and rat leukocyte elastase and cathepsin G. Eur J Biochem. 1984 Oct 1;144(1):1-9. doi: 10.1111/j.1432-1033.1984.tb08423.x.
• [174] Identification of potential biomarkers for predicting acute dermal irritation by proteomic analysis. J Appl Toxicol. 2011 Nov;31(8):762-72.
• [175] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [176] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [177] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [178] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [179] Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003 Aug 15;73(13):1705-19. doi: 10.1016/s0024-3205(03)00515-0.
• [180] BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol. 2012 Dec;92(6):1147-54. doi: 10.1189/jlb.0312165. Epub 2012 Jul 16.
• [181] Methotrexate induced differentiation in colon cancer cells is primarily due to purine deprivation. J Cell Biochem. 2006 Sep 1;99(1):146-55. doi: 10.1002/jcb.20908.
• [182] Cellular reactions to long-term volatile organic compound (VOC) exposures. Sci Rep. 2016 Dec 1;6:37842. doi: 10.1038/srep37842.
• [183] Deoxynivalenol affects in vitro intestinal epithelial cell barrier integrity through inhibition of protein synthesis. Toxicol Appl Pharmacol. 2010 Jun 15;245(3):291-8. doi: 10.1016/j.taap.2010.03.012. Epub 2010 Apr 1.
• [184] Investigation of in vitro odonto/osteogenic capacity of cannabidiol on human dental pulp cell. J Dent. 2021 Jun;109:103673. doi: 10.1016/j.jdent.2021.103673. Epub 2021 Apr 16.
• [185] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [186] Chronic senescent human mesenchymal stem cells as possible contributor to the wound healing disorder after exposure to the alkylating agent sulfur mustard. Arch Toxicol. 2021 Feb;95(2):727-747. doi: 10.1007/s00204-020-02946-5. Epub 2021 Jan 25.
• [187] Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep. 2011 Jan;25(1):41-7.
• [188] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [189] Troglitazone, a PPARgamma ligand, inhibits osteopontin gene expression in human monocytes/macrophage THP-1 cells. J Atheroscler Thromb. 2000;7(2):77-82. doi: 10.5551/jat1994.7.77.
• [190] Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008 Oct;7(10):1607-18.
• [191] Effects of all-trans and 9-cis retinoic acid on differentiating human neural stem cells in vitro. Toxicology. 2023 Mar 15;487:153461. doi: 10.1016/j.tox.2023.153461. Epub 2023 Feb 16.
• [192] Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J Med Chem. 2002 Jul 18;45(15):3310-20. doi: 10.1021/jm0201013.
• [193] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [194] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [195] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [196] Role of phenytoin in wound healing: microarray analysis of early transcriptional responses in human dermal fibroblasts. Biochem Biophys Res Commun. 2004 Feb 13;314(3):661-6. doi: 10.1016/j.bbrc.2003.12.146.
• [197] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [198] Arsenic alters transcriptional responses to Pseudomonas aeruginosa infection and decreases antimicrobial defense of human airway epithelial cells. Toxicol Appl Pharmacol. 2017 Sep 15;331:154-163.
• [199] Activation of fibroblast growth factor (FGF) receptors by recombinant human FGF-5. Oncogene. 1993 May;8(5):1311-6.
• [200] Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array. Pharmacogenomics. 2017 Jul;18(11):1059-1073. doi: 10.2217/pgs-2017-0046. Epub 2017 Jul 7.
• [201] A high concentration of genistein down-regulates activin A, Smad3 and other TGF-beta pathway genes in human uterine leiomyoma cells. Exp Mol Med. 2012 Apr 30;44(4):281-92.
• [202] Increased expression of fibroblast growth factors (FGFs) and their receptor by protamine and suramin on Kaposi's sarcoma-derived cells. Anticancer Res. 1993 Jul-Aug;13(4):887-90.
• [203] The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
• [204] Transcriptomic alterations induced by Ochratoxin A in rat and human renal proximal tubular in vitro models and comparison to a rat in vivo model. Arch Toxicol. 2012 Apr;86(4):571-89.
• [205] Environmental pollutant induced cellular injury is reflected in exosomes from placental explants. Placenta. 2020 Jan 1;89:42-49. doi: 10.1016/j.placenta.2019.10.008. Epub 2019 Oct 17.
• [206] Sulforaphane-induced apoptosis in human leukemia HL-60 cells through extrinsic and intrinsic signal pathways and altering associated genes expression assayed by cDNA microarray. Environ Toxicol. 2017 Jan;32(1):311-328.
• [207] The effect of IFN-gamma and TNF-alpha on the eosinophilic differentiation and NADPH oxidase activation of human HL-60 clone 15 cells. J Interferon Cytokine Res. 2003 Dec;23(12):737-44.
• [208] Impact of rosiglitazone on the expression of beta3-AR in the stable cell lines expressed beta3-AR gene. Clin Chem Lab Med. 2007;45(11):1511-6. doi: 10.1515/CCLM.2007.315.
• [209] Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II. J Med Chem. 2008 Jul 10;51(13):4002-20. doi: 10.1021/jm8000345. Epub 2008 Jun 14.
• [210] Characterization of beta3-adrenoceptors in human internal mammary artery and putative involvement in coronary artery bypass management. J Am Coll Cardiol. 2005 Jul 19;46(2):351-9. doi: 10.1016/j.jacc.2005.03.061.
• [211] Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human -adrenoceptors. J Med Chem. 2011 Oct 13;54(19):6874-87. doi: 10.1021/jm2008562. Epub 2011 Sep 16.
• [212] Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Naunyn Schmiedebergs Arch Pharmacol. 1999 Apr;359(4):310-21. doi: 10.1007/pl00005357.
• [213] Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. doi: 10.1007/s00210-003-0860-y. Epub 2004 Jan 17.
• [214] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [215] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [216] In vitro dual effect of arsenic trioxide on hemopoiesis: inhibition of erythropoiesis and stimulation of megakaryocytic maturation. Blood Cells Mol Dis. 2006 Jan-Feb;36(1):59-76. doi: 10.1016/j.bcmd.2005.10.005. Epub 2005 Dec 15.
• [217] Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31. doi: 10.1289/ehp.10861.
• [218] Gene expression profiling of human peri-implantation endometria between natural and stimulated cycles. Fertil Steril. 2008 Dec;90(6):2152-64.
• [219] Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007 May 15;67(10):5033-41.
• [220] Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res. 2000 Mar;6(3):825-8.
• [221] Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell. 2004 Mar;15(3):1262-72. doi: 10.1091/mbc.e03-06-0360. Epub 2003 Dec 29.
• [222] Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol. 2006 Jan 10;24(2):274-87. doi: 10.1200/JCO.2005.02.9405. Epub 2005 Dec 19.
• [223] Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
• [224] Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs). Toxicol In Vitro. 2010 Sep;24(6):1696-704. doi: 10.1016/j.tiv.2010.05.017. Epub 2010 May 26.
• [225] Induction of the endoplasmic reticulum stress protein GADD153/CHOP by capsaicin in prostate PC-3 cells: a microarray study. Biochem Biophys Res Commun. 2008 Aug 8;372(4):785-91.
• [226] Thalidomide and Its Analogs Differentially Target Fibroblast Growth Factor Receptors: Thalidomide Suppresses FGFR Gene Expression while Pomalidomide Dampens FGFR2 Activity. Chem Res Toxicol. 2019 Apr 15;32(4):589-602. doi: 10.1021/acs.chemrestox.8b00286. Epub 2019 Mar 15.
• [227] Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia. Leukemia. 2003 Dec;17(12):2418-25. doi: 10.1038/sj.leu.2403152.
• [228] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [229] [Effect of inhibiting aquaporin-1 on proliferation and apoptosis of the Hep-2 cell]. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006 Nov;20(21):988-91.
• [230] Evaluation of a human iPSC-derived BBB model for repeated dose toxicity testing with cyclosporine A as model compound. Toxicol In Vitro. 2021 Jun;73:105112. doi: 10.1016/j.tiv.2021.105112. Epub 2021 Feb 22.
• [231] Inorganic arsenic as an endocrine disruptor: modulation of the glucocorticoid receptor pathway in placental cells via CpG methylation. Chem Res Toxicol. 2019 Mar 18;32(3):493-499.
• [232] Novel functional view of the crocidolite asbestos-treated A549 human lung epithelial transcriptome reveals an intricate network of pathways with opposing functions. BMC Genomics. 2008 Aug 7;9:376.
• [233] Molecular characterization of a toxicological tipping point during human stem cell differentiation. Reprod Toxicol. 2020 Jan;91:1-13. doi: 10.1016/j.reprotox.2019.10.001. Epub 2019 Oct 7.
• [234] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [235] Differential effects of omega-3 and omega-6 Fatty acids on gene expression in breast cancer cells. Breast Cancer Res Treat. 2007 Jan;101(1):7-16. doi: 10.1007/s10549-006-9269-x. Epub 2006 Jul 6.
• [236] Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells. Oncogene. 2016 Aug 25;35(34):4518-28. doi: 10.1038/onc.2015.511. Epub 2016 Feb 8.
• [237] Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent. Mol Cancer. 2010 Aug 20;9:220.
• [238] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [239] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [240] Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. J Biochem Mol Toxicol. 2023 Jun;37(6):e23328. doi: 10.1002/jbt.23328. Epub 2023 Feb 19.
• [241] Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells. Toxicol Sci. 2009 Aug;110(2):376-88. doi: 10.1093/toxsci/kfp101. Epub 2009 May 18.
• [242] Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2015 Mar;35(3):1063-76. doi: 10.1111/liv.12626. Epub 2014 Jul 30.
• [243] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [244] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [245] Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-beta-dependent mechanisms. Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):E4558-66.
• [246] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [247] A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One. 2017 May 25;12(5):e0178302. doi: 10.1371/journal.pone.0178302. eCollection 2017.
• [248] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [249] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [250] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [251] Regulation of chromatin assembly and cell transformation by formaldehyde exposure in human cells. Environ Health Perspect. 2017 Sep 21;125(9):097019.
• [252] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [253] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [254] Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
• [255] Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
• [256] Genistein disrupts glucocorticoid receptor signaling in human uterine endometrial Ishikawa cells. Environ Health Perspect. 2015 Jan;123(1):80-7. doi: 10.1289/ehp.1408437. Epub 2014 Aug 19.
• [257] Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod. 2011 Jul;26(7):1813-25.
• [258] Interindividual variation in gene expression responses and metabolite formation in acetaminophen-exposed primary human hepatocytes. Arch Toxicol. 2016 May;90(5):1103-15. doi: 10.1007/s00204-015-1545-2. Epub 2015 Jun 24.
• [259] Gene expression profile of multiple myeloma cell line treated by arsenic trioxide. J Huazhong Univ Sci Technolog Med Sci. 2007 Dec;27(6):646-9. doi: 10.1007/s11596-007-0606-z.
• [260] Characterization of the Molecular Alterations Induced by the Prolonged Exposure of Normal Colon Mucosa and Colon Cancer Cells to Low-Dose Bisphenol A. Int J Mol Sci. 2022 Oct 1;23(19):11620. doi: 10.3390/ijms231911620.
• [261] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [262] Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Biochem Biophys Res Commun. 2009 Sep 18;387(2):342-7. doi: 10.1016/j.bbrc.2009.07.022. Epub 2009 Jul 10.
• [263] Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005 Apr 15;105(8):3286-94. doi: 10.1182/blood-2004-06-2101. Epub 2004 Dec 23.
• [264] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [265] The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
• [266] The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
• [267] Low-dose Bisphenol A exposure alters the functionality and cellular environment in a human cardiomyocyte model. Environ Pollut. 2023 Oct 15;335:122359. doi: 10.1016/j.envpol.2023.122359. Epub 2023 Aug 9.
• [268] Cisplatin induces autophagy to enhance hepatitis B virus replication via activation of ROS/JNK and inhibition of the Akt/mTOR pathway. Free Radic Biol Med. 2019 Feb 1;131:225-236. doi: 10.1016/j.freeradbiomed.2018.12.008. Epub 2018 Dec 11.
• [269] Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
• [270] Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
• [271] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [272] Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells. J Biol Chem. 2002 Nov 15;277(46):43648-58. doi: 10.1074/jbc.M203214200. Epub 2002 Sep 6.
• [273] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [274] Lon protease and eiF2 are involved in acute, but not prolonged, antiretroviral induced stress response in HepG2 cells. Chem Biol Interact. 2016 May 25;252:82-6. doi: 10.1016/j.cbi.2016.03.021. Epub 2016 Apr 1.
• [275] Disease-modifying effects of glucosamine HCl involving regulation of metalloproteinases and chemokines activated by interleukin-1beta in human primary synovial fibroblasts. J Cell Biochem. 2008 May 1;104(1):38-50. doi: 10.1002/jcb.21597.
• [276] Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Sci. 2003 Oct;94(10):886-93.
• [277] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [278] Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics. 2003 Jun;81(6):543-55.
• [279] Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006 Dec 1;66(23):11187-93. doi: 10.1158/0008-5472.CAN-06-1274.
• [280] Prenatal arsenic exposure and shifts in the newborn proteome: interindividual differences in tumor necrosis factor (TNF)-responsive signaling. Toxicol Sci. 2014 Jun;139(2):328-37. doi: 10.1093/toxsci/kfu053. Epub 2014 Mar 27.
• [281] Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve. 2017 Dec;56(6):1077-1084. doi: 10.1002/mus.25733. Epub 2017 Aug 29.
• [282] Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells. PLoS One. 2014 Jan 22;9(1):e86787. doi: 10.1371/journal.pone.0086787. eCollection 2014.
• [283] Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation. BMC Cancer. 2014 Apr 23;14:283.
• [284] Site-specific protein adducts of 4-hydroxy-2(E)-nonenal in human THP-1 monocytic cells: protein carbonylation is diminished by ascorbic acid. Chem Res Toxicol. 2010 Jan;23(1):37-47. doi: 10.1021/tx9002462.
• [285] Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells. Environ Toxicol. 2016 Mar;31(3):314-28.
• [286] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [287] The platelet P2Y12 receptor contributes to granule secretion through Ephrin A4 receptor. Platelets. 2012;23(8):617-25. doi: 10.3109/09537104.2011.645924. Epub 2012 Jan 24.
• [288] Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006 Oct;33(7):875-82. doi: 10.1016/j.nucmedbio.2006.07.004.
• [289] Evaluation of developmental toxicity using undifferentiated human embryonic stem cells. J Appl Toxicol. 2015 Feb;35(2):205-18.
• [290] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
• [291] Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells. J Steroid Biochem Mol Biol. 2003 May;85(1):1-8. doi: 10.1016/s0960-0760(03)00142-0.
• [292] Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid. Liver Int. 2008 Aug;28(7):997-1010. doi: 10.1111/j.1478-3231.2008.01744.x. Epub 2008 Apr 15.
• [293] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [294] RNA sequence analysis of inducible pluripotent stem cell-derived cardiomyocytes reveals altered expression of DNA damage and cell cycle genes in response to doxorubicin. Toxicol Appl Pharmacol. 2018 Oct 1;356:44-53.
• [295] Synergistic effects of retinoic acid and tamoxifen on human breast cancer cells: proteomic characterization. Exp Cell Res. 2007 Jan 15;313(2):357-68. doi: 10.1016/j.yexcr.2006.10.016. Epub 2006 Oct 25.
• [296] Toxicoproteomics reveals an effect of clozapine on autophagy in human liver spheroids. Toxicol Mech Methods. 2023 Jun;33(5):401-410. doi: 10.1080/15376516.2022.2156005. Epub 2022 Dec 19.
• [297] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [298] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [299] Controlled diesel exhaust and allergen coexposure modulates microRNA and gene expression in humans: Effects on inflammatory lung markers. J Allergy Clin Immunol. 2016 Dec;138(6):1690-1700. doi: 10.1016/j.jaci.2016.02.038. Epub 2016 Apr 24.
• [300] Cystathionine metabolic enzymes play a role in the inflammation resolution of human keratinocytes in response to sub-cytotoxic formaldehyde exposure. Toxicol Appl Pharmacol. 2016 Nov 1;310:185-194.
• [301] Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells. Mol Biosyst. 2012 Apr;8(4):1078-87. doi: 10.1039/c2mb05486h. Epub 2012 Jan 10.
• [302] Taurine-responsive genes related to signal transduction as identified by cDNA microarray analyses of HepG2 cells. J Med Food. 2006 Spring;9(1):33-41. doi: 10.1089/jmf.2006.9.33.
• [303] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [304] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [305] An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007 Feb;35(2):252-62.
• [306] In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
• [307] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [308] Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol. 2011 Feb 18;24(2):165-7. doi: 10.1021/tx1004419. Epub 2011 Feb 4.
• [309] Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci. 2011 Mar;120(1):109-22.
• [310] Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity (Silver Spring). 2010 Jan;18(1):27-34. doi: 10.1038/oby.2009.208. Epub 2009 Jun 25.
• [311] Transcriptional profiling in the human prefrontal cortex: evidence for two activational states associated with cocaine abuse. Pharmacogenomics J. 2003;3(1):27-40.
• [312] Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J. 2011 Feb 2;30(3):510-23. doi: 10.1038/emboj.2010.333. Epub 2010 Dec 14.
• [313] Association of Arsenic Exposure with Whole Blood DNA Methylation: An Epigenome-Wide Study of Bangladeshi Adults. Environ Health Perspect. 2019 May;127(5):57011. doi: 10.1289/EHP3849. Epub 2019 May 28.
• [314] Pregnancy exposure to synthetic phenols and placental DNA methylation - An epigenome-wide association study in male infants from the EDEN cohort. Environ Pollut. 2021 Dec 1;290:118024. doi: 10.1016/j.envpol.2021.118024. Epub 2021 Aug 21.
• [315] Suppression of transforming growth factor beta/smad signaling in keloid-derived fibroblasts by quercetin: implications for the treatment of excessive scars. J Trauma. 2004 Nov;57(5):1032-7. doi: 10.1097/01.ta.0000114087.46566.eb.
• [316] Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-trans-retinoic Acid-induced Granulocytic Differentiation in Leukemia Cells. J Biol Chem. 2017 Feb 17;292(7):2815-2829. doi: 10.1074/jbc.M116.745398. Epub 2017 Jan 4.
• [317] Nuclear and Mitochondrial DNA Methylation Patterns Induced by Valproic Acid in Human Hepatocytes. Chem Res Toxicol. 2017 Oct 16;30(10):1847-1854. doi: 10.1021/acs.chemrestox.7b00171. Epub 2017 Sep 13.
• [318] NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. J Biol Chem. 2019 May 24;294(21):8543-8554. doi: 10.1074/jbc.RA118.006983. Epub 2019 Apr 2.
• [319] Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012 Aug;11(8):1703-12.
• [320] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [321] Application of the adverse outcome pathway concept for investigating developmental neurotoxicity potential of Chinese herbal medicines by using human neural progenitor cells in vitro. Cell Biol Toxicol. 2023 Feb;39(1):319-343. doi: 10.1007/s10565-022-09730-4. Epub 2022 Jun 15.
• [322] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [323] Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
• [324] Oxyresveratrol stimulates mucin production in an NAD+-dependent manner in human intestinal goblet cells. Food Chem Toxicol. 2018 Aug;118:880-888.
• [325] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [326] White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nat Cell Biol. 2015 Jan;17(1):57-67. doi: 10.1038/ncb3075. Epub 2014 Dec 8.
• [327] Gene expression alteration during redox-dependent enhancement of arsenic cytotoxicity by emodin in HeLa cells. Cell Res. 2005 Jul;15(7):511-22.
• [328] Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004 Jan;3(1):71-84.
• [329] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [330] Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
• [331] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [332] The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells. Chem Biol Interact. 2019 Apr 1;302:28-35. doi: 10.1016/j.cbi.2019.01.033. Epub 2019 Jan 28.
• [333] Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO). Int J Biochem Cell Biol. 2019 Nov;116:105615. doi: 10.1016/j.biocel.2019.105615. Epub 2019 Sep 17.
• [334] The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915. doi: 10.1016/j.taap.2020.114915. Epub 2020 Feb 6.
• [335] Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells. Eur J Haematol. 2005 Sep;75(3):212-20. doi: 10.1111/j.1600-0609.2005.00498.x.
• [336] Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther. 2002 Jul;1(9):667-77.
• [337] Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses. Cancer Res. 2007 Dec 15;67(24):12007-17. doi: 10.1158/0008-5472.CAN-07-2464.
• [338] Adipogenic Effects and Gene Expression Profiling of Firemaster? 550 Components in Human Primary Preadipocytes. Environ Health Perspect. 2017 Sep 14;125(9):097013. doi: 10.1289/EHP1318.
• [339] Gene expression changes in primary human nasal epithelial cells exposed to formaldehyde in vitro. Toxicol Lett. 2010 Oct 5;198(2):289-95.
• [340] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [341] Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer. Toxicol Appl Pharmacol. 2020 Oct 1;404:115200. doi: 10.1016/j.taap.2020.115200. Epub 2020 Aug 14.
• [342] Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am J Respir Cell Mol Biol. 2008 Sep;39(3):312-23. doi: 10.1165/rcmb.2008-0012OC. Epub 2008 Apr 17.
• [343] Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):355-66.
• [344] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [345] Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environ Toxicol. 2018 Nov;33(11):1168-1181. doi: 10.1002/tox.22623. Epub 2018 Aug 27.
• [346] Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive Mullerian duct cells using microarray. Cancer Lett. 2005 Apr 8;220(2):197-210.
• [347] Gene alterations of ovarian cancer cells expressing estrogen receptors by estrogen and bisphenol a using microarray analysis. Lab Anim Res. 2011 Jun;27(2):99-107. doi: 10.5625/lar.2011.27.2.99. Epub 2011 Jun 22.
• [348] Gamma-irradiation and doxorubicin treatment of normal human cells cause cell cycle arrest via different pathways. Mol Cells. 2005 Dec 31;20(3):331-8.
• [349] Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res. 2005 Aug 1;65(15):6789-800. doi: 10.1158/0008-5472.CAN-04-2684.
• [350] Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen. Cancer Genet Cytogenet. 2006 Apr 15;166(2):130-8. doi: 10.1016/j.cancergencyto.2005.09.012.
• [351] Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:48-54. doi: 10.1016/j.mrgentox.2014.10.011. Epub 2014 Nov 4.
• [352] Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines. Anticancer Res. 2005 Sep-Oct;25(5):3293-302.
• [353] Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res. 2009 May 15;15(10):3406-15. doi: 10.1158/1078-0432.CCR-08-2099. Epub 2009 Apr 28.
• [354] Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia. 2000 Feb;14(2):262-70. doi: 10.1038/sj.leu.2401650.
• [355] 1,25-Dihydroxyvitamin D3 suppresses gene expression of eukaryotic translation initiation factor 2 in human promyelocytic leukemia HL-60 cells. Cell Struct Funct. 2005;30(1):1-6. doi: 10.1247/csf.30.1.
• [356] Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-kappaB signaling axis. Leukemia. 2010 Aug;24(8):1476-86. doi: 10.1038/leu.2010.117. Epub 2010 Jun 3.
• [357] Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol. 2009 Mar;144(5):667-76. doi: 10.1111/j.1365-2141.2008.07504.x. Epub 2008 Nov 20.
• [358] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [359] Transcriptomics and methylomics of CD4-positive T cells in arsenic-exposed women. Arch Toxicol. 2017 May;91(5):2067-2078. doi: 10.1007/s00204-016-1879-4. Epub 2016 Nov 12.
• [360] Early Transcriptomic Changes upon Thalidomide Exposure Influence the Later Neuronal Development in Human Embryonic Stem Cell-Derived Spheres. Int J Mol Sci. 2020 Aug 3;21(15):5564. doi: 10.3390/ijms21155564.
• [361] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [362] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [363] Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002 Jun;16(6):1243-56.
• [364] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [365] Nitric oxide modifies global histone methylation by inhibiting Jumonji C domain-containing demethylases. J Biol Chem. 2013 May 31;288(22):16004-15. doi: 10.1074/jbc.M112.432294. Epub 2013 Apr 1.
• [366] Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9. Oncotarget. 2016 Dec 13;7(50):83359-83377.
• [367] Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659. doi: 10.1002/cam4.1179. Epub 2017 Sep 27.
• [368] Profiling transcriptomes of human SH-SY5Y neuroblastoma cells exposed to maleic acid. PeerJ. 2017 Apr 5;5:e3175.
• [369] Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett. 2004 Oct 8;214(1):19-33.
• [370] Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007 Dec 11;7:223.
• [371] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [372] Expression Profiling of Human Pluripotent Stem Cell-Derived Cardiomyocytes Exposed to Doxorubicin-Integration and Visualization of Multi-Omics Data. Toxicol Sci. 2018 May 1;163(1):182-195. doi: 10.1093/toxsci/kfy012.
• [373] Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.
• [374] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [375] Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane. Bone. 2007 Apr;40(4):876-87. doi: 10.1016/j.bone.2006.11.029. Epub 2006 Dec 28.
• [376] Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells. Toxicology. 2015 Feb 3;328:102-11. doi: 10.1016/j.tox.2014.12.018. Epub 2014 Dec 18.
• [377] Identification of potential biomarkers of hepatitis B-induced acute liver failure using hepatic cells derived from human skin precursors. Toxicol In Vitro. 2015 Sep;29(6):1231-9. doi: 10.1016/j.tiv.2014.10.012. Epub 2014 Oct 24.
• [378] Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia. 2006 Sep;8(9):758-71.
• [379] Quantitative Assessment of Arsenite-Induced Perturbation of Ubiquitinated Proteome. Chem Res Toxicol. 2022 Sep 19;35(9):1589-1597. doi: 10.1021/acs.chemrestox.2c00197. Epub 2022 Aug 22.
• [380] Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int J Cancer. 2008 Apr 1;122(7):1645-56. doi: 10.1002/ijc.23280.
• [381] Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis. Mol Cell Biochem. 2011 Nov;357(1-2):83-94. doi: 10.1007/s11010-011-0878-2. Epub 2011 May 19.
• [382] CARP-1 functional mimetics: a novel class of small molecule inhibitors of medulloblastoma cell growth. PLoS One. 2013 Jun 24;8(6):e66733. doi: 10.1371/journal.pone.0066733. Print 2013.
• [383] New insights into the mechanisms underlying 5-fluorouracil-induced intestinal toxicity based on transcriptomic and metabolomic responses in human intestinal organoids. Arch Toxicol. 2021 Aug;95(8):2691-2718. doi: 10.1007/s00204-021-03092-2. Epub 2021 Jun 20.
• [384] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [385] PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
• [386] Dose- and time-dependent transcriptional response of Ishikawa cells exposed to genistein. Toxicol Sci. 2016 May;151(1):71-87.
• [387] Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013 Mar;3(3):308-23.
• [388] Cloning and characterisation of hAps1 and hAps2, human diadenosine polyphosphate-metabolising Nudix hydrolases. BMC Biochem. 2002 Jul 16;3:20. doi: 10.1186/1471-2091-3-20.
• [389] Effect of mitochondrial dysfunction and oxidative stress on endogenous levels of coenzyme Q(10) in human cells. J Biochem Mol Toxicol. 2011 Sep-Oct;25(5):280-9. doi: 10.1002/jbt.20387. Epub 2011 Feb 9.
• [390] The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 2009 Sep 4;284(36):24306-19.
• [391] Factors determining sensitivity or resistance of tumor cell lines towards artesunate. Chem Biol Interact. 2010 Apr 15;185(1):42-52.
• [392] Human 3D multicellular microtissues: an upgraded model for the in vitro mechanistic investigation of inflammation-associated drug toxicity. Toxicol Lett. 2019 Sep 15;312:34-44.
• [393] Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides. J Biol Chem. 2018 Apr 13;293(15):5600-5612.
• [394] TNF enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett. 2021 May 15;342:73-84. doi: 10.1016/j.toxlet.2021.02.009. Epub 2021 Feb 17.
• [395] Gene expression data from acetaminophen-induced toxicity in human hepatic in vitro systems and clinical liver samples. Data Brief. 2016 Mar 26;7:1052-1057. doi: 10.1016/j.dib.2016.03.069. eCollection 2016 Jun.
• [396] Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
• [397] Gene induction and apoptosis in human hepatocellular carci-noma cells SMMC-7721 exposed to 5-aza-2'-deoxycytidine. Chin Med J (Engl). 2007 Sep 20;120(18):1626-31.
• [398] Progesterone regulation of implantation-related genes: new insights into the role of oestrogen. Cell Mol Life Sci. 2007 Apr;64(7-8):1009-32.
• [399] Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem. 2011 Feb 25;286(8):6602-13.
• [400] Peroxisome proliferator activated receptor gamma (PPAR-gama) ligand pioglitazone regulated gene networks in term human primary trophoblast cells. Reprod Toxicol. 2018 Oct;81:99-107.
• [401] Gene expression profile of the nucleus accumbens of human cocaine abusers: evidence for dysregulation of myelin. J Neurochem. 2004 Mar;88(5):1211-9. doi: 10.1046/j.1471-4159.2003.02247.x.
• [402] Bisphenol A and bisphenol S induce distinct transcriptional profiles in differentiating human primary preadipocytes. PLoS One. 2016 Sep 29;11(9):e0163318.
• [403] Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer. 2006 May 18;5:20. doi: 10.1186/1476-4598-5-20.
• [404] Identification of novel ER-alpha target genes in breast cancer cells: gene- and cell-selective co-regulator recruitment at target promoters determines the response to 17beta-estradiol and tamoxifen. Mol Cell Endocrinol. 2010 Jan 15;314(1):90-100.
• [405] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [406] Antineoplastic effects of gamma linolenic Acid on hepatocellular carcinoma cell lines. J Clin Biochem Nutr. 2010 Jul;47(1):81-90.
• [407] The genomic response of Ishikawa cells to bisphenol A exposure is dose- and time-dependent. Toxicology. 2010 Apr 11;270(2-3):137-49. doi: 10.1016/j.tox.2010.02.008. Epub 2010 Feb 17.
• [408] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [409] Bisphenol-A and estradiol exert novel gene regulation in human MCF-7 derived breast cancer cells. Mol Cell Endocrinol. 2004 Jun 30;221(1-2):47-55. doi: 10.1016/j.mce.2004.04.010.
• [410] Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
• [411] Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.
• [412] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [413] The molecular basis of genistein-induced mitotic arrest and exit of self-renewal in embryonal carcinoma and primary cancer cell lines. BMC Med Genomics. 2008 Oct 10;1:49.
• [414] Epigenetic activation of O-linked -N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. EBioMedicine. 2020 Apr;54:102678. doi: 10.1016/j.ebiom.2020.102678. Epub 2020 Apr 6.
• [415] Ouabain impairs cell migration, and invasion and alters gene expression of human osteosarcoma U-2 OS cells. Environ Toxicol. 2017 Nov;32(11):2400-2413. doi: 10.1002/tox.22453. Epub 2017 Aug 10.
• [416] Use of transcriptomics in hazard identification and next generation risk assessment: A case study with clothianidin. Food Chem Toxicol. 2022 Aug;166:113212. doi: 10.1016/j.fct.2022.113212. Epub 2022 Jun 8.
• [417] Bisphenol A Exposure Changes the Transcriptomic and Proteomic Dynamics of Human Retinoblastoma Y79 Cells. Genes (Basel). 2021 Feb 11;12(2):264. doi: 10.3390/genes12020264.
• [418] Characterizing the genetic basis for nicotine induced cancer development: a transcriptome sequencing study. PLoS One. 2013 Jun 18;8(6):e67252.
• [419] Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression. PLoS One. 2009;4(2):e4409.
• [420] Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer. 2004 Nov 1;112(2):200-12. doi: 10.1002/ijc.20401.
• [421] Cultured human peripheral blood mononuclear cells alter their gene expression when challenged with endocrine-disrupting chemicals. Toxicology. 2013 Jan 7;303:17-24.
• [422] In vitro effects of aldehydes present in tobacco smoke on gene expression in human lung alveolar epithelial cells. Toxicol In Vitro. 2013 Apr;27(3):1072-81.
• [423] Berberine acts as a putative epigenetic modulator by affecting the histone code. Toxicol In Vitro. 2016 Oct;36:10-17. doi: 10.1016/j.tiv.2016.06.004. Epub 2016 Jun 13.
• [424] Ouabain induces apoptotic cell death in human prostate DU 145 cancer cells through DNA damage and TRAIL pathways. Environ Toxicol. 2019 Dec;34(12):1329-1339. doi: 10.1002/tox.22834. Epub 2019 Aug 21.
• [425] Epigallocatechin-3-gallate (EGCG) protects against chromate-induced toxicity in vitro. Toxicol Appl Pharmacol. 2012 Jan 15;258(2):166-75.
• [426] Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells. PLoS One. 2022 Apr 29;17(4):e0266966. doi: 10.1371/journal.pone.0266966. eCollection 2022.
• [427] GLI inhibitors overcome Erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin. J Chemother. 2019 May;31(3):141-149. doi: 10.1080/1120009X.2019.1584422. Epub 2019 Apr 14.
• [428] A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
• [429] Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2011 Feb;123(3-5):140-50.
• [430] Reduced camptothecin sensitivity of estrogen receptor-positive human breast cancer cells following exposure to di(2-ethylhexyl)phthalate (DEHP) is associated with DNA methylation changes. Environ Toxicol. 2019 Apr;34(4):401-414.
• [431] Phenethyl isothiocyanate alters the gene expression and the levels of protein associated with cell cycle regulation in human glioblastoma GBM 8401 cells. Environ Toxicol. 2017 Jan;32(1):176-187.
• [432] Comparative Analysis of Transcriptomic Changes including mRNA and microRNA Expression Induced by the Xenoestrogens Zearalenone and Bisphenol A in Human Ovarian Cells. Toxins (Basel). 2023 Feb 9;15(2):140. doi: 10.3390/toxins15020140.
• [433] Gene-expression profiling during curcumin-induced apoptosis reveals downregulation of CXCR4. Exp Hematol. 2007 Jan;35(1):84-95.
• [434] Preliminary discovery of novel markers for human cell line activation test (h-CLAT). Toxicol In Vitro. 2021 Aug;74:105154. doi: 10.1016/j.tiv.2021.105154. Epub 2021 Mar 25.
• [435] Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
• [436] Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo. Br J Cancer. 2007 Jun 4;96(11):1675-83.
• [437] Estrogen receptor alpha (ER)-mediated coregulator binding and gene expression discriminates the toxic ER agonist diethylstilbestrol (DES) from the endogenous ER agonist 17-estradiol (E2). Cell Biol Toxicol. 2020 Oct;36(5):417-435. doi: 10.1007/s10565-020-09516-6. Epub 2020 Feb 22.
• [438] Oxidative stress modulates expression of immune checkpoint genes via activation of AhR signaling. Toxicol Appl Pharmacol. 2022 Dec 15;457:116314. doi: 10.1016/j.taap.2022.116314. Epub 2022 Nov 9.
• [439] Essential role of HDAC6 in the regulation of PD-L1 in?melanoma. Mol Oncol. 2016 May;10(5):735-750. doi: 10.1016/j.molonc.2015.12.012. Epub 2016 Jan 6.
• [440] Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. Chem Biol Interact. 2021 Nov 1;349:109652. doi: 10.1016/j.cbi.2021.109652. Epub 2021 Sep 11.
• [441] CircRNA VIM silence synergizes with sevoflurane to inhibit immune escape and multiple oncogenic activities of esophageal cancer by simultaneously regulating miR-124/PD-L1 axis. Cell Biol Toxicol. 2022 Oct;38(5):825-845. doi: 10.1007/s10565-021-09613-0. Epub 2021 May 20.
• [442] Simvastatin induces the odontogenic differentiation of human dental pulp stem cells in vitro and in vivo. J Endod. 2009 Mar;35(3):367-72. doi: 10.1016/j.joen.2008.11.024.
• [443] Stimulating effects of quercetin and phenamil on differentiation of human dental pulp cells. Eur J Oral Sci. 2013 Dec;121(6):559-65. doi: 10.1111/eos.12086. Epub 2013 Sep 17.
• [444] Glucosamine promotes osteogenic differentiation of dental pulp stem cells through modulating the level of the transforming growth factor-beta type I receptor. J Cell Physiol. 2010 Oct;225(1):140-51.
• [445] Dentin sialophosphoprotein (DSPP) gene-silencing inhibits key tumorigenic activities in human oral cancer cell line, OSC2. PLoS One. 2010 Nov 12;5(11):e13974. doi: 10.1371/journal.pone.0013974.
• [446] Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
• [447] A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006 Dec;3(12):e486. doi: 10.1371/journal.pmed.0030486.
• [448] The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics. 2010 Aug 13;3:37. doi: 10.1186/1755-8794-3-37.
• [449] Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein. Mol Cell Proteomics. 2011 Jan;10(1):M110.002170.
• [450] Riboflavin deficiency causes protein and DNA damage in HepG2 cells, triggering arrest in G1 phase of the cell cycle. J Nutr Biochem. 2006 Apr;17(4):250-6. doi: 10.1016/j.jnutbio.2005.05.004. Epub 2005 Jun 13.
• [451] Myosin-mediated cytoskeleton contraction and Rho GTPases regulate laminin-5 matrix assembly. Cell Motil Cytoskeleton. 2004 Feb;57(2):107-17. doi: 10.1002/cm.10161.
• [452] Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. Carcinogenesis. 2008 Apr;29(4):779-89.
• [453] Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
• [454] Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta. 2006 Feb;1761(2):205-12. doi: 10.1016/j.bbalip.2005.12.009. Epub 2006 Jan 23.
• [455] An inverse agonist of estrogen-related receptor regulates 2-arachidonoylglycerol synthesis by modulating diacylglycerol lipase expression in alcohol-intoxicated mice. Arch Toxicol. 2020 Feb;94(2):427-438. doi: 10.1007/s00204-019-02648-7. Epub 2020 Jan 7.
• [456] Assessment of mitochondrial toxicity by analysis of mitochondrial protein expression in mononuclear cells. Cytometry B Clin Cytom. 2009 May;76(3):181-90. doi: 10.1002/cyto.b.20458.
• [457] Involvement of mitochondrial dysfunction in nefazodone-induced hepatotoxicity. Food Chem Toxicol. 2016 Aug;94:148-58. doi: 10.1016/j.fct.2016.06.001. Epub 2016 Jun 8.
• [458] Examining the impact of skin lighteners in vitro. Oxid Med Cell Longev. 2013;2013:702120. doi: 10.1155/2013/702120. Epub 2013 Apr 28.
• [459] Chloramphenicol-induced mitochondrial stress increases p21 expression and prevents cell apoptosis through a p21-dependent pathway. J Biol Chem. 2005 Jul 15;280(28):26193-9. doi: 10.1074/jbc.M501371200. Epub 2005 May 19.
• [460] PPARgama activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. Exp Neurol. 2014 Mar;253:16-27.
• [461] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [462] Fumarate Mediates a Chronic Proliferative Signal in Fumarate Hydratase-Inactivated Cancer Cells by Increasing Transcription and Translation of Ferritin Genes. Mol Cell Biol. 2017 May 16;37(11):e00079-17. doi: 10.1128/MCB.00079-17. Print 2017 Jun 1.
• [463] Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer. 2000 Dec 15;88(6):873-80. doi: 10.1002/1097-0215(20001215)88:6<873::aid-ijc6>3.0.co;2-b.
• [464] [Construction of subtracted cDNA library in human Jurkat T cell line induced by arsenic trioxide in vitro]. Zhonghua Yu Fang Yi Xue Za Zhi. 2003 Nov;37(6):403-7.
• [465] Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3767-77.
• [466] Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. Eur J Cancer. 2010 Jul;46(10):1848-55. doi: 10.1016/j.ejca.2010.03.026. Epub 2010 Apr 17.
• [467] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [468] Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
• [469] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [470] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [471] (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
• [472] Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.
• [473] Histamine H4 receptor agonists have more activities than H4 agonism in antigen-specific human T-cell responses. Immunology. 2007 Jun;121(2):266-75. doi: 10.1111/j.1365-2567.2007.02574.x. Epub 2007 Mar 7.
• [474] Examining the genomic influence of skin antioxidants in vitro. Mediators Inflamm. 2010;2010.